|
Post by mindovermatter on Jan 28, 2016 10:38:30 GMT -5
It seems like most around here must have only worked for one company their entire lives? How else could it be that some people have trouble recognizing when a upper-middle management person goes to work for a company that does business with her own? Clearly, while RLS was negotiating with MNKD (before all the ink was dried on RLS's corporate paperwork), they spied Andrea and made her a better offer. Not unheard of. The problem is we do not know why she changed positions. Was it that she saw Mannkind as a dysfunctional company and wanted out? Or is this part of a strategic plan of Mannkind and other entities to move Technosphere along?
|
|
|
Post by mindovermatter on Jan 28, 2016 6:52:45 GMT -5
Hate to ask it, but are they going to sell Afrezza and then take TS private? Mannkind needs to find away to survive so anything is possible. Retail investors will be the last to find out exactly what is going on. Is Andrea no longer with Mannkind a sign of something good or bad? I don't know but obviously when you lose your crown jewel scientist typically is a not a good sign. But, her ending up at Receptor Life Sciences, that just struck a deal with Mannkind is something to pay attention to.
|
|
|
Post by mindovermatter on Jan 28, 2016 5:20:03 GMT -5
Andrea Linked inChief Scientific Officer Receptor Life Sciences October 2015 – Present (4 months) making it easy for others RECEPTOR LIFE SCIENCES, INC. UBI Number 603568334 Category REG Profit/Nonprofit Profit Active/Inactive Active State Of Incorporation WA WA Filing Date 12/16/2015Expiration Date 12/31/2016 www.sos.wa.gov/corps/search_detail.aspx?ubi=603568334If it is true that RLS was newly formed in December 2015 as per the above info, my question is: Why Andrea Leone Bay states she has been hired as CSO by RLS since October 2015 (before its existence)? She could be fired for lying on her CV!
|
|
|
Post by mindovermatter on Jan 28, 2016 5:13:16 GMT -5
The company needs money desperately. If they can find a suitable buyer for Afrezza, one that they believe can do the leg work that Sanofi was unwilling to do to make Afrezza successful, I believe they will sell it to that company so that it can use the money to further TS applications. IMO Afrezza, sad to say, is a anchor around the neck of this company. Yikes... do I need to change my name from dreamboatcruise to dreamboatanchor? I am feeling that I set out for a 3 hour cruise and got shipwrecked. Hopefully you have Maryanne and Ginger to console you. My wife slaps me every time I utter their names in my sleep. And in deed, hang in there little buddy.
|
|
|
Post by mindovermatter on Jan 27, 2016 14:34:07 GMT -5
They've engaged an IB and they told investors they are exploring all opportunities. The IB has undoubtedly been tasked with exactly that. The only question is whether in answering this poll yes or no you are wanting us to weigh in on Al's state of mind regarding likelihood of agreeing to a buyout anywhere near what is realistic price. Even if management hadn't said they were exploring all opportunities, I think it would be a breach of their fiduciary duties to not be at this point... and having said they are would add a layer of deception if they are not.kc ... yes... you are correct $10 would be "nice"... sort of like it would be "nice" if I had won that billion dollar lottery. I think realistically, they have to consider all options. But importantly, with all these spawning lawyer PRs on breach of duty. If they did not, lawyers would have a field day, "case closed". Geez. Reminds me of B. Clinton's joke years ago after the impeachment scandal when he said he'd log into AOL and hear, "You've got subpoenas" .... The company needs money desperately. If they can find a suitable buyer for Afrezza, one that they believe can do the leg work that Sanofi was unwilling to do to make Afrezza successful, I believe they will sell it to that company so that it can use the money to further TS applications. IMO Afrezza, sad to say, is a anchor around the neck of this company.
|
|
|
Post by mindovermatter on Jan 27, 2016 13:00:30 GMT -5
Difficult day for shorts? What about the devastating 18 months for longs?
|
|
|
Post by mindovermatter on Jan 27, 2016 8:50:10 GMT -5
MNKD doesn't sell here if Al Mann is not happy with whatever offer he can get. My gut tells me he won't be happy at all, and therefore, no sale. Al didn't start MNKD to make money- he started it as a philanthropic effort. He was already a billionaire and publicly stated that he didn't want to leave his fortune to his children. He's not in this for the money, although he's not in it to lose money either. If they are entertaining any deals, it's not because they're trying to profit on the company. It's because they're being forced to sell out of inevitable bankruptcy. I don't know Al personally, so this comment might seem silly, but I can almost guarantee you that he wouldn't hand over this company to someone else unless he needed to. He'd much rather keep it in the hands of those whom he appointed and trusts. Al is no dummy nor are the people managing his money. He knew that Mannkind was a risky venture and that Afrezza wouldn't be a slam dunk. So how do you think he has hedged his Mannkind investment. In light of the drastic hair cut Mannkind has taken, his net worth has had to take a huge hit. He is no longer a billionaire unless he hedged. If he did hedge his bet with Afrezza, just how did he do it?
|
|
|
Post by mindovermatter on Jan 27, 2016 6:17:06 GMT -5
If Mannkind is seriously considering selling Afrezza or itself, I would think it would want to get a deal done prior to the April 4th hand over if possible.
|
|
|
Post by mindovermatter on Jan 26, 2016 17:17:11 GMT -5
The fact this story is out and out by Reuters is not by mistake. The company is up for sale. The question now is whether or not it will get a reasonable sales price that will get the nod from Al. This story was out on the Day the SNY termination was announced it was on the Dow Jones Wire service.
DOW JONES & COMPANY, INC. 10:05 AM ET 1/5/2016 Symbol Last Price Change MNKD 1.05down -0.4 (-27.59%) SNY 42.23down +0.03 (+0.07%) QUOTES AS OF 11:05:27 AM ET 01/05/2016 MannKind Corp. (MNKD) on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled diabetes medicine Afrezza and signaled that it might look to sell the drug.
Shares of the company tumbled 28% in early trading. Over the past three months, shares have dropped 67%, including Tuesday's decline.
MannKind (MNKD) said that it and Sanofi(SNY) would begin transition talks to return Afrezza to MannKind(MNKD) over the next three to six months, with the termination effective no later than July 4. As a result of squashed deal, MannKind(MNKD) said it is reviewing its strategic options for Afrezza. The evaluation of options typically include a full or partial sale.
The company struck the marketing deal with French drug company Sanofi(SNY) in August 2014. In its most recent quarterly earnings call with analysts and investors, then-Chief Executive Hakan Edstrom said MannKind(MNKD) was "disappointed with the growth of Afrezza sales during the first nine months of the year," pointing to insurance reimbursement issues and slow uptake. Mr. Edstrom stepped down as CEO in November.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
(END) Dow Jones Newswires 01-05-161105ET Copyright (c) 2016 Dow Jones & Company, Inc
Read more: mnkd.proboards.com/user/284/recent#ixzz3yO2xyIrO
You are confusing two separate things. One is the author of the Jan 5th article making the assumption that one strategic option usually discussed is a sale of the company and today which is the anonymous confirmation that the company is actually pursuing that option. So not exactly the same thing as you are misreading the first quote.
|
|
|
Post by mindovermatter on Jan 26, 2016 15:46:33 GMT -5
This is FUD. The quote is "Mannkind is working with investment bankers on options". That doesn't mean the company is up for sale. Matt would be crazy to not explore all the options for raising funds. But, anyone thinking Al wants out has a greater than 99% chance of being wrong. This isn't an "article" this its a rumor. The fact this story is out and out by Reuters is not by mistake. The company is up for sale. The question now is whether or not it will get a reasonable sales price that will get the nod from Al.
|
|
|
Post by mindovermatter on Jan 26, 2016 15:18:19 GMT -5
Doesn't posting complete articles from newspapers, magazines, and news agencies such as Reuters violate copyright laws? Links are OK, as are brief quotes, but not complete articles. Posting whole articles without the expressed consent of the publisher is ILLEGAL.
|
|
|
Post by mindovermatter on Jan 26, 2016 6:29:14 GMT -5
If you are in at $11 or $5 I would say you are in trouble. I am in at 83 cents and 66 cents. If it gets over a $1 or even back to its $1.50 $2.00 range I am happy! Not sure what the next few months will hold. I will tell you 1 of the Vanguard funds has about 5 million shares of this stock or at least they did 2 months ago. I am not suggesting that this will happen anytime soon, but good news can do wonders to push a stock up. Remove the vast swirling winds of uncertainty around Mannkind and the share price will rebound. As to what exactly will do that, who knows. But if the robber barons on Wall Street change their sentiment to positive, watch out. Mannkind will fly. And to be clear, I am not saying this is going to happen but I've seen it with other in the dumpster biotech stocks.
|
|
|
Post by mindovermatter on Jan 25, 2016 14:05:35 GMT -5
Ok, so let's all agree it is a Paul Allen and a few other really well off investors. If we can figure it out so can Wall Street and by the looks of it the Steet doesn't care. But how does that help Mannkind at all at this point knowing who RLS is possibly controlled by? I am much more interested in how Mannkind is going to undue all the negativity surrounding itself and Afrezza and get Afrezza into the hands of those who could really use it. That's a story I am patiently waiting Mannkind to relay to its investors who have been destroyed.
|
|
|
Post by mindovermatter on Jan 23, 2016 18:36:19 GMT -5
And look at the bright side. While no one on here knows who Receptor is, no one on Wall Street does either. I'm just anxious to see who is involved in the company backing. Illumina just spun off a new company named Grail and Gates and Bezos are backers for about $100 million. So Receptor Life Sciences not only has money to fund operations but also $102.5 million to pay MNKD milestones? I'm actually positive on this deal because it certainly adds to help concrete their business model but again we are left in the dark about the partnership/partner. I know many people are anxious to find out who is behind Receptor but honestly (in my best Hillary Clinton voice) "what difference does it make?" If the company has no approved drugs and are years away from getting one approved, do you think Wall street is really going to care if it is Bill Gates or Google or Apple? Wall Street see Mannkind as a dead company and will continue to beat it with their short stick until Mannkind can show it can make money. It's just that simple.
|
|
|
Post by mindovermatter on Jan 22, 2016 20:49:12 GMT -5
For the hell of it, I sent another email to Receptor asking, "How do I find you on Tinder?"
|
|